Jiangsu Hengrui Medicine
600276.SS
#489
Rank
A$65.09 B
Marketcap
$10.20
Share price
-1.55%
Change (1 day)
1.58%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

EPS for Jiangsu Hengrui Medicine (600276.SS)

EPS in 2023 (TTM): $0.14

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current EPS (TTM) is $0.14. In 2022 the company made an earnings per share (EPS) of $0.14 a decrease over its 2021 EPS that were of $0.17.

EPS history for Jiangsu Hengrui Medicine from 2002 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.14-2.55%
2022$0.14-17.1%
2021$0.17-24.44%
2020$0.2220.3%
2019$0.1925.58%
2018$0.1527.55%
2017$0.1221.64%
2016$0.0955113.57%
2015$0.0841039.86%
2014$0.0601321.33%
2013$0.0495617.7%
2012$0.0421025.56%
2011$0.0335326.22%
2010$0.0265710.3%
2009$0.0240957.92%
2008$0.0152511.06%
2007$0.0137385.81%
2006$0.00739187.94%
2005$0.00393233.97%
2004$0.00293529.78%
2003$0.00226219.78%
2002$0.001888